AcquisitionsApr 6, 2026, 11:54 AM
Neurocrine Biosciences to Acquire Soleno Therapeutics for $53 per Share in Cash
AI Summary
Soleno Therapeutics has entered into a definitive agreement to be acquired by Neurocrine Biosciences for $53 per share in cash. The acquisition will occur via a tender offer followed by a merger, making Soleno a wholly-owned subsidiary of Neurocrine. This represents a significant premium for Soleno shareholders and provides Neurocrine with access to Soleno's pipeline or assets.
Key Highlights
- Neurocrine Biosciences will commence a cash tender offer to purchase all outstanding shares of Soleno at $53 per share.
- The offer is subject to customary closing conditions, including the tender of a majority of Soleno's outstanding shares.
- Following the tender offer, a merger will occur, with Soleno becoming a wholly-owned subsidiary of Neurocrine.